To the editor regarding article “Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study”
Main Authors: | Florian J. Mayer, Gerfried Pesau, Gerit H. Schernthaner |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-12-01
|
Series: | Diabetology & Metabolic Syndrome |
Online Access: | http://link.springer.com/article/10.1186/s13098-018-0394-6 |
Similar Items
-
Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study
by: Yi-Hsuan Lin, et al.
Published: (2018-10-01) -
Renoprotective Effects of DPP-4 Inhibitors
by: Daiji Kawanami, et al.
Published: (2021-02-01) -
Clinical Use of DPP-4 Inhibitors
by: Baptist Gallwitz
Published: (2019-06-01) -
Sitagliptin: the world’s first DPP-4 inhibitor
by: N. A. Petunina, et al.
Published: (2019-08-01) -
Diabetes and bone. Focus on DPP-4 inhibitors
by: A. Y. Babenko, et al.
Published: (2015-12-01)